title: How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.
authors.affiliation: From Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
authors.forename: Marisa
authors.initials: M
authors.lastname: Battistella
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Chan
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D015519:Bone Density; D000068256:Darbepoetin alfa; D004351:Drug Resistance / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000628:therapy*
chemical_list: D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa